Gilead CEO Daniel O'Day (Credit: Georgios Kefalas/AP)
November 7, 2019 07:21 AM ESTUpdated 10:36 AM
Pharma
FDA+

HHS is tak­ing Gilead to court, seek­ing dam­ages for in­fring­ing gov­ern­ment HIV patents

Natalie Grover

Reporter

Gilead ear­li­er this year fired an open­ing sal­vo by march­ing to the US Patent and Trade­mark Of­fice and re­quest­ing a re­view of the

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

FDA says Ozem­pic, We­govy short­age is over

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Pfiz­er ends roll­out of Be­qvez, putting an­oth­er dent in he­mo­phil­ia gene ther­a­py field

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times